182 related articles for article (PubMed ID: 36034783)
1. Clinical Efficacy and
Huang Y; Wang W; Huang Q; Wang Z; Xu Z; Tu C; Wan D; He M; Yang X; Xu H; Wang H; Zhao Y; Tu M; Zhou Q
Front Pharmacol; 2022; 13():944965. PubMed ID: 36034783
[No Abstract] [Full Text] [Related]
2.
Huang Y; Zhou Q; Wang W; Huang Q; Liao J; Li J; Long L; Ju T; Zhang Q; Wang H; Xu H; Tu M
Front Pharmacol; 2019; 10():92. PubMed ID: 30814950
[No Abstract] [Full Text] [Related]
3. Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia.
Motos A; Yang H; Li Bassi G; Yang M; Meli A; Battaglini D; Cabrera R; Bobi J; Pagliara F; Frigola G; Camprubí-Rimblas M; Fernández-Barat L; Rigol M; Ferrer-Segarra A; Kiarostami K; Martinez D; Nicolau DP; Artigas A; Pelosi P; Vila J; Torres A
Crit Care; 2023 Feb; 27(1):60. PubMed ID: 36788582
[TBL] [Abstract][Full Text] [Related]
4. Amikacin and cefoperazone/sulbactam alone or in combination against carbapenem-resistant Pseudomonas aeruginosa.
Cai Y; Yang D; Wang J; Wang R
Diagn Microbiol Infect Dis; 2018 Jun; 91(2):186-190. PubMed ID: 29486972
[TBL] [Abstract][Full Text] [Related]
5. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
Zhao C; Xie W; Zhang W; Ye Z; Wu H
Zhonghua Shao Shang Za Zhi; 2014 Apr; 30(2):166-70. PubMed ID: 24989663
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Combined Ciprofloxacin and azithromycin free and nano formulations to control biofilm producing Pseudomonas aeruginosa isolated from burn wounds.
Raouf M; Essa S; El Achy S; Essawy M; Rafik S; Baddour M
Indian J Med Microbiol; 2021 Jan; 39(1):81-87. PubMed ID: 33460732
[TBL] [Abstract][Full Text] [Related]
8.
Li X; Le W; Lou X; Wang B; Genco CA; Rice PA; Su X
Microbiol Spectr; 2021 Oct; 9(2):e0018121. PubMed ID: 34668731
[TBL] [Abstract][Full Text] [Related]
9. A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam.
Xia J; Zhang D; Xu Y; Gong M; Zhou Y; Fang X
Int J Infect Dis; 2014 Jun; 23():90-3. PubMed ID: 24726664
[TBL] [Abstract][Full Text] [Related]
10. The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs.
Borgatta B; Gattarello S; Mazo CA; Imbiscuso AT; Larrosa MN; Lujàn M; Rello J
Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2155-2163. PubMed ID: 28624864
[TBL] [Abstract][Full Text] [Related]
11. Surprising synergy of dual translation inhibition vs. Acinetobacter baumannii and other multidrug-resistant bacterial pathogens.
Dillon N; Holland M; Tsunemoto H; Hancock B; Cornax I; Pogliano J; Sakoulas G; Nizet V
EBioMedicine; 2019 Aug; 46():193-201. PubMed ID: 31353294
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.
Albiero J; Mazucheli J; Barros JPDR; Szczerepa MMDA; Nishiyama SAB; Carrara-Marroni FE; Sy S; Fidler M; Sy SKB; Tognim MCB
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910903
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
Sader HS; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
[TBL] [Abstract][Full Text] [Related]
14. [Risk factors and etiological analysis of ventilator-associated pneumonia: three year's cases analysis of intensive care unit in county hospital].
Hu Z; Zhou S
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2018 Oct; 30(10):933-938. PubMed ID: 30439311
[TBL] [Abstract][Full Text] [Related]
15. Synergistic Activity of Berberine with Azithromycin against Pseudomonas Aeruginosa Isolated from Patients with Cystic Fibrosis of Lung In Vitro and In Vivo.
Li Y; Huang J; Li L; Liu L
Cell Physiol Biochem; 2017; 42(4):1657-1669. PubMed ID: 28738346
[TBL] [Abstract][Full Text] [Related]
16. [The combination effects of antibacterial agents against clinical isolated multiple-drug resistant Pseudomonas aeruginosa].
Maesaki S; Yamaguchi T; Sasaki K; Hashikita G; Shibuya S; Watanabe M; Takayama S; Kawakami S; Nagasawa M; Suzuki N; Uchida T; Okabe T; Kobayashi S;
Jpn J Antibiot; 2006 Feb; 59(1):11-20. PubMed ID: 16673578
[TBL] [Abstract][Full Text] [Related]
17. [In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].
Turk Dagi H; Kus H; Arslan U; Tuncer I
Mikrobiyol Bul; 2014 Apr; 48(2):311-5. PubMed ID: 24819268
[TBL] [Abstract][Full Text] [Related]
18. Antibiotics Combinations and Chitosan Nanoparticles for Combating Multidrug Resistance
Banoub NG; Saleh SE; Helal HS; Aboshanab KM
Infect Drug Resist; 2021; 14():3327-3339. PubMed ID: 34447258
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel targets of azithromycin activity against
Belanger CR; Lee AH; Pletzer D; Dhillon BK; Falsafi R; Hancock REW
Proc Natl Acad Sci U S A; 2020 Dec; 117(52):33519-33529. PubMed ID: 33318204
[No Abstract] [Full Text] [Related]
20. Synergy of drug combinations in treating multidrug-resistant Pseudomonas aeruginosa.
Rizvi M; Ahmad J; Khan F; Shukla I; Malik A; Sami H
Australas Med J; 2015; 8(1):1-6. PubMed ID: 25848402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
